Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Chronic Hepatitis C

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Chronic Hepatitis C in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caini, P; Giannelli, F; Giannini, C; Gragnani, L; Guerra, CT; Laffi, G; Monti, M; Petrarca, A; Solazzo, V; Zignego, AL2

Other Studies

2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Chronic Hepatitis C

ArticleYear
Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:1

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Antiviral Agents; Apolipoprotein B-100; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrophages; Male; Middle Aged; Platelet Activating Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Viremia

2007
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 1

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Apolipoprotein B-100; Carrier State; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrophages; Male; Middle Aged; Platelet Activating Factor; RNA, Viral; Vasculitis

2007